News articles about MannKind Corporation (NASDAQ:MNKD) have trended very positive this week, Accern Sentiment reports. The research firm identifies negative and positive media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. MannKind Corporation earned a news impact score of 0.52 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 89 out of 100, indicating that recent media coverage is very likely to have an impact on the stock’s share price in the immediate future.
MNKD has been the topic of several research analyst reports. S&P Equity Research reduced their price target on shares of MannKind Corporation from $1.04 to $0.83 in a research report on Monday, May 8th. J P Morgan Chase & Co reaffirmed an “underweight” rating on shares of MannKind Corporation in a research report on Monday, May 22nd. ValuEngine cut shares of MannKind Corporation from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. Finally, Piper Jaffray Companies set a $1.00 price target on shares of MannKind Corporation and gave the stock a “sell” rating in a research report on Thursday, May 11th.
MannKind Corporation (MNKD) opened at 1.16 on Wednesday. The company has a market cap of $117.17 million, a PE ratio of 0.82 and a beta of 3.33. MannKind Corporation has a 12 month low of $0.67 and a 12 month high of $5.85. The stock’s 50 day moving average is $1.43 and its 200 day moving average is $1.11.
MannKind Corporation (NASDAQ:MNKD) last issued its earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.09) by $0.08. The firm had revenue of $3 million for the quarter, compared to analyst estimates of $3.50 million. During the same quarter in the prior year, the business posted ($0.06) EPS. The business’s quarterly revenue was up 2900.0% compared to the same quarter last year. Equities analysts predict that MannKind Corporation will post ($0.87) earnings per share for the current year.
About MannKind Corporation
MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control.
Receive News & Ratings for MannKind Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind Corporation and related companies with our FREE daily email newsletter.